Company: DAWN
Filing Date: 2025-04-11
Form Type: DEF 14A
Source: 0001140361-25-013462
Chunk: 16

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-04-11
Form: DEF 14A
Chunk 16
---
-based compensation plans; and |

| • | overseeing our compliance with regulatory requirements associated with the compensation of directors, officers and employees. |

Our board of directors has also established an equity granting committee that is composed of our Chief Executive Officer to make ordinary course equity awards grants to employees that are not our executive officers or non-employee directors, subject to certain limitations on the equity grant amounts per grantee and aggregate grant amounts. Nominating and Corporate Governance Committee Our nominating and corporate governance committee is composed of Garry Nicholson, John Josey and Habib Dable. Dr. Josey is the chair of our nominating and corporate governance committee. The members of our nominating and corporate governance committee meet the independence requirements under Nasdaq and SEC rules and regulations. Our nominating and corporate governance committee is responsible for, among other things:

| • | identifying, considering and recommending candidates for membership on our board of directors; |

| • | developing and recommending corporate governance guidelines and policies for the company; |

| • | overseeing the evaluation our board of directors and its committees; |

| • | advising our board of directors on corporate governance matters; |

| • | assisting our board of directors in overseeing and advising the board of directors on any related matters required by the federal securities laws; and |

| • | assisting the board of directors in overseeing any company program relating to corporate responsibility and sustainability. |

Compensation Committee Interlocks and Insider Participation The members of our compensation committee during the year ended December 31, 2024 included Dr. Grossman, Mr. Nicholson, Ms. Holles and Dr. Becker. None of the members of the compensation committee in fiscal year 2024 was at any time during fiscal year 2024 or at any other time an officer or employee of ours or any of our subsidiaries, and none had or have any relationships with us that are required to be disclosed under Item 404 of Regulation S-K. During fiscal year 2024, none of our executive officers served on the board of directors or compensation committee, of any entity that has one or more executive officers who served on our board of directors or compensation committee. Anti-Hedging We have adopted an Insider Trading Policy that applies to all of our directors, officers, employees and our extended workforce, including our Chief Executive Officer and other executive officers. Among other prohibited activities, the Insider Trading Policy prohibits individuals from engaging in hedging or monetization transactions, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds